Anthivera

Trending

What’s trending in peptides.

The peptide products women are actually searching for and buying, ranked by real-world demand — then graded on the evidence.

Trending is not the same as recommended. This list reflects what’s popular — search volume, sales, and marketing muscle. The grade beside each entry is our independent read of the evidence, which often points the other way. Popularity is a measure of attention, not proof.

Evidence grade — our read, independent of the ranking

  • FDA-approvedFDA-approved for the use in question.
  • Some evidenceReal human data, though usually modest.
  • Thin evidenceSmall, preliminary, or largely animal data.
  • Mostly hypePopular well beyond what the evidence supports.
  • Claim invertedThe evidence points the opposite way from the marketing.
Sort by
  1. demand

    Semaglutide (Ozempic / Wegovy)

    Metabolic · GLP-1FDA-approved

    Why it’s trending: The best-selling drug franchise in the world (~$48B) and the most-searched peptide by far — ~1.5M US searches a month. Oral Wegovy launched January 2026.

    Our read: FDA-approved for weight management and type 2 diabetes. The women's questions that matter most — muscle and bone loss, hair shedding, pregnancy — are the ones the ads skip.

    Read: GLP-1 medications for women →
  2. demand

    Tirzepatide (Mounjaro / Zepbound)

    Metabolic · GLP-1FDA-approved

    Why it’s trending: The fastest-growing GLP-1 and second most-searched peptide (~823K US searches a month), with weight outcomes that often run ahead of semaglutide.

    Our read: FDA-approved and effective, but not yet in our catalog. Same muscle-, bone-, and hair-loss cautions apply — the hair-loss signal is notably higher in women.

    Read: GLP-1 and hair loss in women →
  3. demand

    BPC-157

    RecoveryThin evidence

    Why it’s trending: The research peptide most people start with, and the most-searched of the non-GLP-1 peptides (~74K US searches a month), marketed for joint, tendon, and gut repair.

    Our read: Animal data is genuinely interesting; human evidence is roughly three small studies. Removed from FDA Category 2 in April 2026 and recommended for the 503A list at the July PCAC review — but that's advisory only and it can't yet be legally dispensed on that basis.

    See the BPC-157 entry →
  4. demand

    Copper peptide serums (GHK-Cu)

    Skin · CosmeticSome evidence

    Why it’s trending: The fastest-rising cosmetic peptide. Copper-peptide serums like The Ordinary Multi-Peptide + Copper are beauty-aisle bestsellers.

    Our read: The best-supported topical peptide for skin — multiple human studies for firmness and hydration — but results are subtle and take months. Injectable forms are a separate, more-regulated story.

    See the GHK-Cu entry →
  5. demand

    Matrixyl / palmitoyl-peptide serums

    Skin · CosmeticThin evidence

    Why it’s trending: The default 'anti-wrinkle peptide' in most serums on the shelf, from budget to prestige.

    Our read: Modest, real, and oversold. Small, often manufacturer-funded studies show mild fine-line improvement — and most cosmetic peptides struggle to even penetrate the skin barrier.

    Read: do peptide serums actually work? →
  6. demand

    "GLP-1 for hair" add-ons

    Marketing bundleClaim inverted

    Why it’s trending: A fast-spreading Instagram/DTC pitch — pairing a GLP-1 program with a hair-growth 'support' product.

    Our read: The evidence runs the other way: GLP-1s are associated with hair loss, and the risk is higher in women (about 7% vs under 1% in men in tirzepatide trials). A seller pairing the two is worth a hard look.

    Read: GLP-1 and hair loss in women →
  7. demand

    CJC-1295 + Ipamorelin (GH-axis stack)

    Hormone · GH-axisThin evidence

    Why it’s trending: The classic growth-hormone-axis pairing sold by peptide clinics for body composition, sleep, and recovery.

    Our read: Small, short human studies. CJC-1295 in particular carries a more cautious regulatory status — don't let a clinic treat it as interchangeable with ipamorelin or sermorelin.

    See the CJC-1295 entry →
  8. demand

    Longevity peptides (NAD+, MOTS-c, epithalon)

    LongevityMostly hype

    Why it’s trending: The fastest-rising category by growth rate, riding the broader longevity wave — heavily marketed, thinly studied.

    Our read: Mechanistically interesting, but human evidence for the anti-aging claims is preliminary at best. Popularity here is running well ahead of the data.

How we rank

Demand, not endorsement. Ranking reflects real-world popularity as of September 2026 — US search volume, published sales and market data, and how heavily a product is advertised to women. A high rank means many people are looking; it says nothing about whether they should be.

The grade is separate. Each grade is our independent read of the evidence — from FDA-approved down to mostly hype — decided the same way as our peptide entries. When popularity and evidence disagree, we say so plainly.